health Genetic Testing Carefree Senior Living at Waltonwood Twelve Oaks Waltonwood Twelve Oaks caters to seniors who desire social opportunities, luxury amenities, and access to personal care services if needed. With a great location and warm, caring staff, you will feel right at home as soon as you step foot inside. Rental community with no buy-in fee! Save When You Sign a 12 Month Lease* by May 31, 2018: Independent Living $750 off monthly rent for first year and no Community Fee Assisted Living & Memory Care 3rd month rent free and no Community Fee *For new move-ins only Stop by or call and schedule a personal tour today. 248-567-2060 Independent Living | Licensed Assisted Living | Memory Care 27475 Huron Circle, Novi, MI 48377 Located across from Twelve Oaks Mall Waltonwood.com | SinghJobs.com 70 April 26 • 2018 jn Using our heritage to fi nd a cure for Parkinson’s disease. BARBARA ANDERSON, M.D. SPECIAL TO THE JN A neurodegenerative disorder whose cause is unknown, Parkinson’s disease was first described in 1817 as “shaking palsy” by James Parkinson, for whom the condition is named. The onset of symptoms — tremors, slowness and stiffness, walking and balance issues, and a host of non-movement symptoms, including depression, con- stipation and cognitive decline — is generally slow, and their progression varies among individuals. Treatment options, too, vary, and include medica- tions and surgery. Although Parkinson’s disease is not fatal, complications of the disease, according to the Centers for Disease Control and Prevention, are the 14th cause of death in the U.S. April is Parkinson’s Awareness Month, and in honor of the 1 million people living with Parkinson’s disease in the United States, I want to share my story. You may know that Ashkenazi Jews can trace their ancestry to just 350 individuals. This heritage has created genetic similarities so acute that, according to scientists, “everyone is a 30th cousin.” With gene mutations passed from generation to generation, Ashkenazi Jews are more likely to carry genetic variants that increase risk of certain conditions, including Parkinson’s dis- ease. This unique ancestry presents a treasure trove of data for genetic researchers and a powerful oppor- tunity to improve the kind of disease mapping that can speed cures. I don’t have Parkinson’s myself but am a daughter, daughter-in-law and sister to individuals diagnosed with the disease — and I know too well the difficulty and frustration that Parkinson’s causes millions of people and their loved ones, especially because the disease has no cure. Given my family history and Ashkenazi Jewish descent, I wanted to know my genetic status. Because of genetic counseling and testing, I learned I carry mutations in both my LRRK2 and GBA1 genes, each of which is associated with increased risk for Parkinson’s. My husband, Jay, also carries a mutation in the GBA1 gene. So, we set out to do everything in our power to learn more about Parkinson’s and test therapies to stop its progression. Together, we enrolled in the Parkinson’s Progression Markers Initiative (PPMI), a study sponsored by the Michael J. Fox Foundation, to share our data and biosamples (blood and spinal fluid) to help scientists learn more about this disease and, most important, speed research that may lead to cures. Jay and I support the study by par- ticipating in imaging tests and clinical exams, and by contributing biosam- ples annually. We’ve made this com- mitment because we know the only way we’re going to fight this disease is with knowledge, and this kind of data is our best hope for unlocking the key to new therapies. If we’re not willing to volunteer that data, then nothing is ever going to change. I hope you’ll join us. • Barbara Robinson, M.D. is an obstetrician- gynecologist near Chicago. This story first appeared on reformjudaism.org. The PPMI study is seeking people of Ashkenazi Jewish descent who themselves have either Parkinson’s or Gaucher’s disease (given a GBA1 connection between the two) or have a first-degree relative who has either disease. The study is enrolling people with a mutation in the LRRK2 or GBA1 gene and provides free genetic testing to identify potential participants, as well as genetic counseling. To learn more about Parkinson’s disease and the PPMI study, visit the Michael J. Fox Foundation for Parkinson’s Research at www.michaeljfox.org.